Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial

被引：0
|
作者：
Chen, H. [1 ]
Hu, Y. [2 ]
Fan, Y. [3 ]
Wu, G. [4 ]
Cang, S. [5 ]
Yang, Y. [6 ]
Yang, N. [7 ]
Ma, R. [8 ]
Jing, G. [9 ]
Liu, A. [10 ]
Xu, X. [11 ]
Tang, S. [12 ]
Cheng, Y. [13 ]
Yu, Y. [14 ]
Wu, Y-L. [1 ]
机构：
[1] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp,Guangdong Acad Med Sc, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Peoples R China
[2] Hubei Canc Hosp, Dept Thorac Oncol, Wuhan, Peoples R China
[3] Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[4] Meizhou Peoples Hosp, Dept Oncol, Meizhou, Peoples R China
[5] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China
[6] Third Peoples Hosp Chendu, Dept Thorac Surg, Chengdu, Peoples R China
[7] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Med Oncol,Xiangya Sch Med, Changsha, Peoples R China
[8] Liaoning Canc Hosp, Med Oncol, Dept Thorac Canc, Shenyang, Peoples R China
[9] Inner Mongolia Autonomous Reg Peoples Hosp, Dept Oncol, Hohhot, Peoples R China
[10] Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Peoples R China
[11] Wuhan Univ, Dept Oncol, Renmin Hosp, Hubei Gen Hosp, Wuhan, Peoples R China
[12] First Peoples Hosp Neijiang, Dept Oncol, Neijiang, Peoples R China
[13] Jilin Canc Hosp, Med Oncol, Changchun, Peoples R China
[14] Harbin Med Univ, Dept Internal Med, Canc Hosp, Harbin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22P
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 50 条
  • [1] The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.
    He, Zhiyong
    Lin, Jinghui
    He, Yueming
    Zhang, Jing
    Yang, Dongyong
    Qiu, Wenbin
    Lai, Jinhuo
    Chen, Xi
    Fang, Wenzheng
    Ye, Feng
    Xu, Tianwen
    Wu, Huita
    Qiu, Dongfa
    Chen, Wujin
    Cai, Lifang
    Chen, Shengchi
    Lin, Qunying
    Lin, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial
    Yang, Lu
    Yang, Sheng
    Liu, Yutao
    Li, Junling
    Hu, Xingsheng
    Wang, Yalei
    Zhang, Yan
    Wang, Yan
    THORACIC CANCER, 2018, 9 (06) : 693 - 698
  • [3] A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
    Chen, Hua-Jun
    Tu, Hai-Yan
    Hu, Yanping
    Fan, Yun
    Wu, Guowu
    Cang, Shundong
    Yang, Yi
    Yang, Nong
    Ma, Rui
    Jin, Gaowa
    Xu, Ximing
    Liu, Anwen
    Tang, Shubin
    Cheng, Ying
    Yu, Yan
    Xu, Chong-Rui
    Zhou, Qing
    Wu, Yi-Long
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [4] EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer
    Sheng, Zhixin
    Zhang, Yanxia
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 7
  • [5] EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer
    Zhixin Sheng
    Yanxia Zhang
    Medical Oncology, 2015, 32
  • [6] Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study
    Lu, Shun
    Zhou, Jian-Ying
    Niu, Xiao-Min
    Zhou, Jian-Ya
    Jian, Hong
    Yin, Hong-Yan
    Guan, Sha
    Wang, Lin-Fang
    Li, Ke
    He, James
    Su, Wei-Guo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 839 - +
  • [7] The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer
    Xiang, Hai
    Danna, Ding
    Xuefei, Chen
    Zhao, Jinkai
    Jin, Guangjun
    ANTI-CANCER DRUGS, 2024, 35 (05) : 433 - 439
  • [8] Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial
    Chen, X.
    Shen, J.
    Li, X.
    Yang, S.
    Xia, B.
    Wang, B.
    Wang, J.
    Zheng, S.
    Zhao, P.
    Ma, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S877 - S877
  • [9] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [10] Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
    Wang, Xiaohong
    Liu, Yonggang
    Meng, Zhiying
    Wu, Yun
    Wang, Shubin
    Jin, Gaowa
    Qin, Yingchun
    Wang, Fengyun
    Wang, Jing
    Zhou, Haifei
    Su, Xiaoxing
    Fu, Xiuhua
    Wang, Xiaolan
    Shi, Xiaoyu
    Wen, Zhenping
    Jia, Xiaoqiong
    Qin, Qiong
    Gao, Yongqiang
    Guo, Weidong
    Lu, Shun
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
12345